Literature DB >> 17352371

Nonsurgical management of primary hyperparathyroidism.

Bryan Farford1, R John Presutti, Thomas J Moraghan.   

Abstract

Primary hyperparathyroidism is the most common cause of hypercalcemia in the outpatient setting and is typically caused by a single benign parathyroid adenoma. Most patients with hyperparathyroidism are postmenopausal women. Patients can be asymptomatic or minimally symptomatic. Parathyroidectomy is the definitive cure for primary hyperparathyroidism, and no medical therapies have been approved by the Food and Drug Administration for this disorder. Guidelines for surgery have been established by a National Institutes of Health consensus panel, but many patients do not meet these guidelines or have comorbid conditions that prohibit surgery. This review describes alternative treatment options for patients who decide against or are unable to proceed with surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17352371     DOI: 10.4065/82.3.351

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

Review 1.  Mild primary hyperparathyroidism: a literature review.

Authors:  Megan K Applewhite; David F Schneider
Journal:  Oncologist       Date:  2014-07-25

2.  Evaluation and therapy of hypercalcemia.

Authors:  Nadia Khoury; Kim A Carmichael
Journal:  Mo Med       Date:  2011 Mar-Apr

3.  Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.

Authors:  G Akbaba; S Isik; Y Ates Tutuncu; U Ozuguz; D Berker; S Guler
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 4.256

4.  Percutaneous Ultrasound-Guided Laser Ablation with Contrast-Enhanced Ultrasonography for Hyperfunctioning Parathyroid Adenoma: A Preliminary Case Series.

Authors:  Tianan Jiang; Fen Chen; Xiang Zhou; Ying Hu; Qiyu Zhao
Journal:  Int J Endocrinol       Date:  2015-12-16       Impact factor: 3.257

5.  Ultrasound-guided ethanol injection for the treatment of parathyroid adenoma: A prospective self-controlled study.

Authors:  Amir Ali Yazdani; Nooshin Khalili; Mansour Siavash; Albert Shemian; Amir Reza Goharian; Mozhgan Karimifar; Babak Tavakoli; Maryam Yazdi
Journal:  J Res Med Sci       Date:  2020-10-28       Impact factor: 1.852

6.  Atorvastatin lowers serum calcium levels in lithium-users: results from a randomized controlled trial.

Authors:  Jocelyn Fotso Soh; Katie Bodenstein; Harmehr Sekhon; Soham Rej; Oriana Hoi Yun Yu; Outi Linnaranta; Suzane Renaud; Artin Mahdanian; Chien-Lin Su; Istvan Mucsi; Benoit Mulsant; Nathan Herrmann; Tarek Rajji; Serge Beaulieu
Journal:  BMC Endocr Disord       Date:  2022-09-24       Impact factor: 3.263

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.